Pharmafile Logo

Merrimack Pharma

ASCO 2015: What you missed in Chicago

Blue Latitude sent two of our consultants to Chicago to attend ASCO 2015, a key annual meeting for oncology specialists that brings over 30,000 delegates together to talk about innovations...

Blue Latitude Health

Pharma deals in May 2015

The number of corporate acquisitions drops, finds Medius Deal Watch

- PMLiVE

Amgen and Merck to expand cancer collaboration

Firms to test Keytruda in combination for cancers inside the head and neck

- PMLiVE

Rise in cancer therapy costs ‘unsustainable’ says oncologist

Leonard Saltz made the claims in his keynote presentation at ASCO

- PMLiVE

Afinitor set for filing this year in neuroendocrine cancer

Novartis drug is already approved for breast and renal cancers

- PMLiVE

Ipsen acquires OctreoPharm to boost its oncology presence

Will aid the development of its approach to neuroendrocrine tumours

- PMLiVE

Endo buys Par for $8bn as M&A mania marches on

Acquisitionwill make Endo the fifth largest generics company in the US

Pharma deals in April 2015

The love affair with oncology continues, finds Medius Deal Watch

Medius Deal Watch table for April 2015

The top major pharma mergers, acquisitions and collaborations during the month continued pharma's love affair with oncology

- PMLiVE

Merck KGaA, Threshold gain FDA fast-track review

Industry partners hope their new cancer drug will be approved by the end of the year

Pharma deals in March 2015

AbbVie's Pharmacyclics mega-merger dominated the month, finds Medius Deal Watch

Medius Deal Watch table for March 2015

The top major pharma mergers, acquisitions and collaborations during the month were dominated by AbbVie's Pharmacyclics mega-merger

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links